Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. Founded in 1984, Dr. Reddy's is one of India's largest pharmaceutical companies with a significant global presence, particularly in generic medications, active pharmaceutical ingredients (APIs), and proprietary products. The company has developed a substantial portfolio of generic central nervous system (CNS) medications[1].
| Attribute | Value |
|---|---|
| Founded | 1984 |
| Headquarters | Hyderabad, India |
| NSE | DRREDDY |
| BSE | 500078 |
| Market Cap | ~$10 billion (2026) |
| Revenue | ~$3 billion (FY2025) |
| Employees | ~22,000 |
Dr. Reddy's has a comprehensive portfolio of generic neurology medications:
| Category | Products | Notes |
|---|---|---|
| Parkinson's Disease | Levodopa, Carbidopa, Entacapone | Generic combinations |
| Epilepsy | Valproic acid, Carbamazepine, Lamotrigine | First-line generics |
| Stroke | Aspirin, Clopidogrel | Antiplatelet agents |
| Migraine | Sumatriptan, Rizatriptan | Acute treatment |
| Category | Products | Notes |
|---|---|---|
| Depression | Escitalopram, Sertraline, Venlafaxine | SSRIs and SNRIs |
| Schizophrenia | Risperidone, Olanzapine, Quetiapine | Atypical antipsychotics |
| Anxiety | Lorazepam, Clonazepam | Benzodiazepines |
| Bipolar Disorder | Lithium, Valproate | Mood stabilizers |
| Category | Products | Notes |
|---|---|---|
| Neuropathic Pain | Gabapentin, Pregabalin | First-line generics |
| Acute Pain | Tramadol, Diclofenac | NSAIDs and opioids |
| Chronic Pain | Amitriptyline, Nortriptyline | TCAs |
Dr. Reddy's invests in proprietary drug development:
| Product | Mechanism | Stage | Indication |
|---|---|---|---|
| DRR-001 | Novel analgesic | Phase 1 | Chronic pain |
| DRR-02 | CNS modulator | Discovery | Depression |
Dr. Reddy's operates multiple manufacturing facilities:
| Location | Focus |
|---|---|
| Hyderabad, India | API and formulations |
| Visakhapatnam, India | API manufacturing |
| Mysore, India | Biologics |
| US (New Jersey) | Packaging and distribution |
FY2025 Revenue: ₹27,000 crore (~ billion)
R&D Investment: ~8% of revenue
US ANDA Approvals: 15+ in FY2025
Generic Drug Manufacturers
Dr. Reddy's Laboratories Ltd. Corporate Overview. 2026. ↩︎